179 related articles for article (PubMed ID: 20077040)
1. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS
Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
4. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
7. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
10. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
[TBL] [Abstract][Full Text] [Related]
11. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Ryu MH; Baba E; Lee KH; Park YI; Boku N; Hyodo I; Nam BH; Esaki T; Yoo C; Ryoo BY; Song EK; Cho SH; Kang WK; Yang SH; Zang DY; Shin DB; Park SR; Shinozaki K; Takano T; Kang YK;
Ann Oncol; 2015 Oct; 26(10):2097-101. PubMed ID: 26216386
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo H; Yu Z; Gao H; Guan C; Xu M
J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
Kang BW; Kim JG; Chae YS; Lee YJ; Lee SJ; Moon JH; Sohn SK; Jung MK; Jeon SW; Jang YJ; Seo J; Lee YH; Kwon O; Chung HY; Yu W
Invest New Drugs; 2012 Aug; 30(4):1671-5. PubMed ID: 21845514
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
17. [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Hyodo I
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():64-7. PubMed ID: 16897974
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
[TBL] [Abstract][Full Text] [Related]
20. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
